U.S. Markets close in 4 hrs 33 mins
  • S&P 500

    3,446.98
    +20.06 (+0.59%)
     
  • Dow 30

    28,354.04
    +158.62 (+0.56%)
     
  • Nasdaq

    11,525.61
    +46.73 (+0.41%)
     
  • Russell 2000

    1,623.69
    +10.07 (+0.62%)
     
  • Crude Oil

    40.62
    -0.21 (-0.51%)
     
  • Gold

    1,911.40
    -0.30 (-0.02%)
     
  • Silver

    24.84
    +0.15 (+0.60%)
     
  • EUR/USD

    1.1829
    +0.0056 (+0.4731%)
     
  • 10-Yr Bond

    0.7820
    +0.0210 (+2.76%)
     
  • Vix

    29.23
    +0.05 (+0.17%)
     
  • GBP/USD

    1.2959
    +0.0018 (+0.1426%)
     
  • USD/JPY

    105.5600
    +0.1300 (+0.1233%)
     
  • BTC-USD

    11,953.91
    +896.90 (+8.11%)
     
  • CMC Crypto 200

    240.65
    +1.74 (+0.73%)
     
  • FTSE 100

    5,900.43
    +15.78 (+0.27%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes

Shanthi Rexaline

Biotech stocks haven't seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals: Horizon Therapeutics PLC's (NASDAQ: HZNP) thyroid eye disorder drug and Epizyme Inc's (NASDAQ: EPZM) tazemetostat for epithelioid sarcoma.

The Wuhan coronavirus scare triggered strong moves in stocks of companies working on treatment/vaccines for the deadly virus.

Here are the key catalysts that could impact trading in biotech stocks in the unfolding week.

Conferences

12th Annual T-cell Lymphoma Forum: Jan. 30–Feb. 1 in San Diego, California

PDUFA Dates

Aimmune Therapeutics Inc (NASDAQ: AIMT) has a target action date of end of January for its peanut allergy treatment candidate Palforzia. An Adcom that evaluated the experimental therapy voted 7-to-2 in favor of the efficacy of Palforzia and 8-to-1 in favor of its safety.

View more earnings on IBB

See Also: 7 Blockbuster Drugs Expected To Be Launched In 2020

Clinical Readouts

Miragen Therapeutics Inc (NASDAQ: MGEN) will make a poster presentation of data from the Phase 1 trial of cobomarsen, a miR inhibitor in patients with aggressive HTLV-1 Associated adult T-cell leukemia/lymphoma. The presentation is scheduled for Friday evening.

Earnings Tuesday

  • Pfizer Inc. (NYSE: PFE) (before the market open)

Wednesday

  • Illumina, Inc. (NASDAQ: ILMN) (after the market close)

  • Varian Medical Systems, Inc. (NYSE: VAR) (after the market close)

  • Hologic, Inc. (NASDAQ: HOLX)

Thursday

  • Quest Diagnostics Inc (NYSE: DGX) (before the market open)

  • Eli Lilly And Co (NYSE: LLY) (before the market open)

  • Biogen Inc (NASDAQ: BIIB) (before the market open)

  • Amgen, Inc. (NASDAQ: AMGN) (after the market close)

  • Edwards Lifesciences Corp (NYSE: EW) (after the market close)

IPOs

Anpac Bio-Medical Science, which focuses on early cancer screening and detection, has filed to offer 17.50 million shares in an IPO, which is expected to be priced between $14 and $16. The company is seeking to list its shares on the Nasdaq under the ticker symbol "ANPC."

Arcutis Biotherapeutics, a biotech company developing topical therapies for common skin diseases, proposes to offer 7.8 million shares at a price range of $15-$17. The shares are to be listed on the Nasdaq under the ticker symbol "ARQT."

Black Diamond Therapeutics, a precision oncology company, is planning an 8.9-million share IPO to be priced between $16 and $18. The company expects to list the shares on the Nasdaq under the ticker symbol "BDTX."

0

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.